Chronic obstructive pulmonary disease (COPD) causes a Background: major burden in terms of deaths and hospitalizations worldwide; it is associated with progressive lung function loss, and frequent exacerbations. Administration of macrolides has been considered beneficial in reducing the frequency of COPD exacerbations. The aim of this study is to assess the safety and efficacy of long-term administration of Azithromycin for patients with chronic obstructive pulmonary disease.
Introduction
Chronic obstructive pulmonary disease (COPD) is "a disease state characterized by airflow limitation that is not fully reversible" 1 . It is a progressive life threatening lung disease, with frequent symptoms that include: chronic cough, breathlessness, and sputum production 2 . It is the fourth leading cause of death worldwide affecting more than 60 million people and it is estimated to become the third by 2030. 3.2 million deaths occur due to COPD, with 90% of them occurring in middle and low income countries [3] [4] [5] . Until now, there is no definitive treatment for COPD and thus effective management of COPD relies on improving health status, reducing the mortality, as well as preventing and treating complications and exacerbations of the disease 6 . COPD exacerbation is defined as "an acute worsening of respiratory symptoms that result in additional therapy", and classified as mild (responsive to short acting bronchodilators), moderate (requiring antibiotics and/or oral corticosteroids in addition to short acting bronchodilators), or severe (requiring hospitalization) 7 . Numerous international guidelines have discussed recommendations about the benefits of antimicrobial agents in patients with acute exacerbation of COPD, as they are more prone to develop bacterial infections [8] [9] [10] . Among these antimicrobial agents, macrolides (such as Azithromycin) are especially favored as prophylactic antibiotics in COPD, mostly due to their potentially beneficial anti-inflammatory and immunomodulatory roles, in addition to their known antibacterial effect 11 .
Azithromycin belongs to macrolides family; it is a semisynthetic antibiotic derived from another macrolide, erythromycin. Azithromycin has bactericidal and bacteriostatic properties, hence it is used in treating certain bacterial infections 12 . Azithromycin acts by binding reversibly to the 50S ribosomal subunit of the 70S ribosome of the targeted bacteria, thereby inhibiting the translocation step of protein synthesis stopping bacterial growth 13 .
Several studies have discussed the beneficial role of macrolides for COPD patients [14] [15] [16] [17] [18] [19] , some of them suggested that long-term Azithromycin therapy has been shown to decrease the rate of recurrence and severity of exacerbations of COPD 20,21 . However, there is little evidence as to whether Azithromycin is safe and efficacious for management of COPD; thus our study aims to evaluate the efficacy and safety of long-term administration of Azithromycin therapy for chronic obstructive pulmonary disease by accumulating the evidence from randomized control trials that studied the efficacy and safety of Azithromycin administration for COPD patients.
Methods

Search strategy
We systematically searched the literature on PubMed and Scopus databases, as well as the Cochrane central register of controlled trials (CENTRAL) and ClinicalTrials.gov register clinical trial registers. We searched using the terms; chronic obstructive pulmonary disease, exacerbation, chronic bronchitis, emphysema, Azithromycin. The electronic search string used for PubMed was as follows: (((chronic obstructive pulmonary disease OR chronic bronchitis) OR emphysema) AND exacerbation) AND Azithromycin. Our search was limited to human studies only. Our last search was on January 24, 2018. Moreover, hand searching was done by screening the reference lists of all included studies ( Figure 1 ).
Inclusion criteria
Our eligibility criteria for studies to be included in our metaanalysis were: (1) Randomized controlled trials that included only stable COPD patients in any stage of the disease. (2) COPD is defined clinically as [forced expiratory volume in 1 second (FEV 1) /forced vital capacity (FVC)] <70%, FEV 1 <80% predicted, and an increase in FEV 1 <12% (or 200 ml) after inhaling bronchodilators, according to Tiffeneau-Pinelli Index 22 . (3) Studies that used Azithromycin. (4) The drug was administered orally and the therapy lasted more than two weeks. (5) Information about clinical efficacy or the safety of the drug were reported.
Studies selection
Four reviewers, AA, KA, AA, and HA screened the titles and abstracts of the search results independently for potentially eligible studies. After removing duplicates and irrelevant records, they independently reviewed the full-text of potentially eligible studies using the previously mentioned inclusion criteria. Any differences between the reviewers were solved through consensus. There were no disagreements that needed to be resolved by the senior author.
Data extraction and quality assessment
We measured the risk of bias for all studies that fulfilled our inclusions criteria using RevMan 5.3 software (Cochrane Collaboration, Copenhagen, Denmark) risk of bias assessment tool using: allocation concealment, random sequence generation, blinding of participants and personnel, incomplete outcome data, blinding of outcome assessment, selective reporting as the main parameters for bias. The information that we extracted from the selected studies were study setting information, patients' characteristics information, treatment information (dosage, therapy strategy, course of therapy, concomitant medication to treat COPD), frequency of exacerbations, and adverse events reports. The reviewers extracted this information independently. Output RevMan file used for analysis is available as Underlying data 23 . 
Statistical analyses
We used random-effects models to pool treatment effects and to calculate the risk ratios (RR) with 95% CI for all clinical end-points, which were the frequencies of exacerbations. All types of exacerbations (mild, moderate, and severe) were included in the pooled analysis with no distinction between them, because some of the included studies reported severe exacerbations while others reported non severe exacerbations. To examine the robustness of the effect we performed a sensitivity analysis by removing the trials with the highest weights and computing the overall estimates for the remaining studies. Regarding statistical heterogeneity, we used the I2 statistic on a scale of 0-100% (>50% indicated a statistical between-study inconsistency, and >75% represented a very large degree of heterogeneity). Subgroup analysis were performed for two strata of data, dosage of Azithromycin used (250 mg Azithromycin or 500 mg Azithromycin) and the duration of the administration (3 months or 12 months). Funnel plot method was used to assess the publication bias. P < 0.05 was considered statistically significant. RevMan 5.3 software (Cochrane Collaboration, Copenhagen, Denmark) was used to perform the pooling analyses of the data.
Results
Studies identification and selection
Initially 1031 published records were identified (677 from SCOPUS, 199 from PubMed, 15 from ClinicalTrials.gov register, and 140 from CENTRAL) ( Figure 1 ). 4 studies 24-27 meet the inclusion criteria. 1348 participants were included in the four trials, the follow-up duration varied among the studies: 3 months 25 , 6 months 27 , and 12 months 24, 26 . Of the total number of participants in the included trials, 674 participants were randomly assigned to receive Azithromycin, while 674 were allocated to receive Placebo; in addition both groups continued receiving their concomitant medications (long acting β2 agonists, long acting anticholinergics, inhaled corticosteroids, short acting β2 agonists, oral Prednisolone) ( Table 1) , Azithromycin dosages used were 250 mg Azithromycin 24,25,27 and 500 mg Azithromycin 26 .
The duration of Azithromycin therapy was for 3 months 25, 27 and 12 months 24,26 , the total number of withdrawals among the selected studies was 66. Three studies 24,26,27 compared the frequency of acute exacerbation difference that occurred during the follow-up period between the Azithromycin group and the Placebo group using Poisson regression model. One study 25 reported acute exacerbations as percentages for both of the study groups. All four studies reported the adverse events that occurred during the follow-up period. In addition to acute exacerbations rate and the adverse events, other outcomes like health related quality of life 24-27 , bacterial culture, macrolides resistance 24,26,27 , and pulmonary functions test 25-27 were also reported.
Qualitative data synthesis
The time to the first acute exacerbation of COPD in days was higher among patients who received Azithromycin compared patients who received the Placebo 24-26 . Uzun et al. revealed that hospital admission odds ratio did not differ between the two groups 26 , however, according to the other studies hospital admissions were reported more amongst the Placebo group 24,25,27 . Furthermore, chest computed tomography symptom score did not show any difference between the two groups 27 , and after 12 weeks of Azithromycin therapy a significant increase in the Leicester Cough Questionnaire total score was reported in the Azithromycin group compared with the Placebo. Pulmonary function test was conducted in all four studies [24] [25] [26] [27] , with the exception of Albert et al., all indicated that no significant difference in the test results were reported between Azithromycin and Placebo groups.
Nasopharyngeal colonization was assessed in three studies 24,26,27 , two of them 24, 26 reported that fewer patients in the Azithromycin group had positive culture during the course of the study (p value < 0.001, p value= 0.044 respectively) while the other 27 reported no difference between the Azithromycin and Placebo group. Macrolide-resistant bacteria were detected more in the Azithromycin group of Simpson et al., in which the incidence of resistance was 81% among Azithromycin group, and 41% in the placebo (p value < 0.001) 27 , however it was detected more among the Placebo group with 24%, in contrast to 6% among Azithromycin group (p value = 0.036) from Uzun et al. 26 . Nasopharyngeal colonization was not associated with the occurrence of acute exacerbations in either group (p value 0.31) 24 .
Quality of life was recorded using different tools: St George Respiratory Questionnaire (SGRQ) 24-27 , Short-form 36 Health Survey (SF-36) 24,25 , and the 12-Item Short Form Health Survey (SF-12) 26 . Three studies 24-26 reported a decrease in SRGQ total scores in the Azithromycin group compared with the Placebo group, however one study 27 reported no decrease in the total score among Azithromycin group. The results of the SF-36 scores varies among studies as one study 24 stated that no changes were seen in the scores while the other study 25 reported a significant difference in the scores between Azithromycin and Placebo groups. In addition, the mean change differed significantly between the Placebo group and the Azithromycin group in the mental component score of SF-12 26 . The most commonly reported adverse event was hearing decrement which was reported in 18% (252) of the participants, an audiogram-confirmed hearing decrement occurred more frequently in participants receiving Azithromycin compared to those receiving Placebo (P=0.04), however, audiogram-confirmed hearing decrement was used in only one study 24 . Table 2 demonstrates the side effects that occurred among the patients.
Quantitative data synthesis
The final analysis of the pooled data of the all three trials showed that administration of Azithromycin reduced the frequency of acute exacerbation of COPD [risk ratio (RR) = 0.69: 95% CI 0.53, 0.91, p = 0.008] (Figure 2 ). Subgroup analysis of Azithromycin dosage ( (Figure 3 ), subgroup analysis of Azithromycin dosage and therapy duration ( Table 4 ) reported no significant difference between Azithromycin and Placebo groups in developing adverse events.
Regarding the risk of bias assessment, the included studies had low risk of bias. Additionally, sensitivity analysis and publication bias sensitivity analysis on the frequency of acute exacerbation performed by deleting the highest weight trial 24 revealed no significant difference on the results (p value changed to 0.03).
In addition, sensitivity analysis on the adverse events performed by deleting the highest weight trials 24,27 also revealed no significant difference on the results (p value changed to 0.36). Furthermore, regarding publication bias analysis, funnel plots of both acute exacerbation frequency and adverse events were symmetrical. In regard to heterogeneity among the studies, 77% heterogeneity was found among the frequency of acute exacerbation meta-analysis studies, while 33% was found among adverse events meta-analysis studies.
Discussion
Long-term administration of Azithromycin was associated with reduction in the frequency of acute exacerbation among COPD patients, similar findings have been detected among cystic fibrosis patients 28 , however Yao and colleagues deduced that Erythromycin was more effective than Azithromycin in decreasing acute exacerbation frequency 29 .
Many studies have investigated the immunomodulatory effects of macrolides, like decreasing the synthesis of pro-inflammatory cytokines in response to viral infections 30 , decreasing the hypersecretion of pro-inflammatory cytokines and chemokines 31 , enhancement of phagocytosis function of alveolar macrophages 32 , and preserving airway epithelial integrity 33 . Moreover, in addition to the immunomodulatory effects, the decrease in airway bacterial colonization in patients receiving Azithromycin might also be linked to the reduction in the systemic inflammation 34 since infections are the most common cause of acute exacerbation 7 .
The statistical pooling of the data revealed that 500 mg dose of Azithromycin is superior to 250 mg dose, however this results is not enough to draw a conclusion that it is more beneficial, since there is only one study included in the meta-analysis that used a 500 mg dose with only 92 patients in contrast to 1256 patients that were included in the studies that used a 250 mg dose.
Moreover, In the meta-analysis, no difference was found regarding the development of adverse events between the Azithromycin group and the Placebo group even at 500 mg dose and for 12 months' therapy duration, in contrast to a previous meta-analysis, which revealed that nonfatal adverse events (gastrointestinal reactions, ototoxicity, rash, and liver injury) were associated with the Placebo group. In addition, hearing decrement occurred more frequently in participants receiving Azithromycin compared to those receiving Placebo, but the improvements in hearing that occurred on repeat testing, suggested that hearing decrements were overestimated in both groups. Gastrointestinal adverse events were the second most common encountered, conversely, they were the most common side effects reported in two previous studies 28, 29 . nevertheless, the usage of serial audiometry was only in one study while the other included studies report no usage of audiometry in assessing hearing decrement among the participants, this might have led to underreporting of adverse events in these studies, which may in turn have led eventually to this result in the meta-analysis.
Additionally In summary, this study revealed that, long-term Azithromycin administration for COPD patients is not statistically associated with increased risk of developing adverse events, yet three studies did not perform serial audiometry which might have led to under reporting of the adverse events. Furthermore, there is a lack of differentiation between intermittent and daily dosing in the adverse events meta-analysis, these limitations might proscribe such a conclusion. In addition, the results of the pooled data suggest that Azithromycin is effective in reducing the frequency of acute exacerbation of COPD, and the use of Azithromycin may be beneficial for COPD patients.
Only four studies were included in this review, more studies are required to confirm our findings especially regarding dosage and adverse events.
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